Achillion Pharma (ACHN) Posts Narrower-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Achillion (ACHN) Decline Called Over-Reaction at Deutsche Bank
November 4, 2014 11:23 AM ESTDeutsche Bank maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $17. The stock declined Tuesday after it reported Q3 results. Analyst Alethia Young thinks today's decline on concerns about the timing of 3422 data is an overreaction.
"Based on our call volume, we have gotten questions as to whether this is a delay or not. We have always... More
Achillion Pharma (ACHN): Hard to Read Anything into Absence of 3422 Data, Says Wells Fargo
November 4, 2014 10:17 AM ESTWells Fargo maintained an Outperform rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $15-$17. Comments follow Q3 results. Analyst Brian Abrahams noted Achillion did not provide data on its 3422 nuc, but he thinks it's on track to be... More
